Madri­gal’s got more pos­i­tive da­ta for resme­tirom, plus news from Ali­gos and North­Sea

The Amer­i­can As­so­ci­a­tion for the Study of Liv­er Dis­eases is set to hold its an­nu­al Liv­er Meet­ing this week­end in Boston. This morn­ing, we round­ed up some of the late-break­ing da­ta shared in ad­vance of the up­com­ing event.

Madri­gal Ther­a­peu­tics pre­sent­ed more pos­i­tive da­ta from a Phase III tri­al of its NASH drug can­di­date, adding fu­el to the com­pa­ny’s plans to win the first-ever ap­proval in the chal­leng­ing in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER